Compare ProShares UltraPro QQQ ETF (TQQQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs Zimmer Biomet Holdings Inc — how do they compare? ProShares UltraPro QQQ ETF trades at $81.33 (market cap $38.74B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 2.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro QQQ ETF for 24 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TQQQ | ZBH | |
|---|---|---|
Market Cap | $38.74B | $16.95B |
Volume | 65,384,797 | 2,505,240 |
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $103.98 |
52-Week Low | $37.89 | $79.58 |
Typical Hold Time | 24 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $81.28, down 2.78% on the day, with technical indicators showing a bullish bias despite recent selling pressure. The ETF maintains a strong position near its pivot point of $81, supported by positive moving average signals. Recent news highlights ongoing institutional interest alongside concerns about hidden costs and volatility risks inherent in leveraged ETF structures.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face significant volatility risks amplified by the 3x leverage structure. Key opportunities include exposure to Nasdaq-100 growth, while risks center on expense ratios, financing costs, and potential market corrections that could magnify losses.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
